U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07460245) titled 'Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma' on Feb. 23.
Brief Summary: This study represents an innovative opportunity in the treatment of metastatic urothelial carcinoma
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Urothelial Carcinoma
Intervention:
DRUG: Avelumab 800 mg flat-dose IV
Avelumab 800 mg flat-dose IV every 2 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Published by HT Digital Content Services with permission from Health Daily Digest....